TYK2 and autoimmune disease: The downregulated type I IFN‐associated gene expression suggested that Deu@Cal MN therapy may prevent autoimmune cell activation, and treat autoimmune diseases with a predominant role for type I IFN, such as cutaneous lupus.[30] The reduced neutrophil infiltration in the lesion suggested that Deu@Cal MNs could inhibit the formation of new lesions, such as those seen in the Koebner phenomenon.[31] Moreover, Deu@Cal MN therapy could also regulate the TYK2‐STAT cascade, indicating its protection from multiple autoimmune and inflammatory disorders.